Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: A retrospective case review study

BMC Cancer

Volumn 9, Issue , 2009, Pages 338-

  Ardavanis, Alexandros ^a   Doufexis, Dimitrios ^a   Kountourakis, Panteleimon ^a   Malliou, Savvoula ^a   Karagiannis, Athanasios ^a   Kardara, Evgenia ^a   Sykoutri, Despina ^a   Charalampia, Margari ^a   Rigatos, Gerasimos ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTERY THROMBOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DISEASE COURSE; DRUG FATALITY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; QUALITY OF LIFE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; VEIN THROMBOSIS;

EID: 70449358685     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-338     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Stöger H, Hegenbarth K. Angiogenesis as a therapeutic target in advanced breast cancer. Magazine of European Medical Oncology 2008, 1:9-12.
3. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997, 57(5):963-969.
4. Sridhar SS, Shepherd FA. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003, 42(Suppl 1):S81-91. 10.1016/S0169-5002(03)00308-8, 14611919.
5. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003, 21(4):588-592. 10.1200/JCO.2003.08.013, 12586793.
6. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20(12):2812-2823. 10.1200/JCO.2002.09.002, 12065558.
7. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23(4):792-799. 10.1200/JCO.2005.05.098, 15681523.
8. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357(26):2666-2676. 10.1056/NEJMoa072113, 18160686.
9. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649-655. 10.1097/00000421-198212000-00014, 7165009.
10. Park JO, Lee SI, Song SY, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH. Measuring response in solid tumors: comparison of RECIST and WHO response criteria. Jpn J Clin Oncol 2003, 33(10):533-537. 10.1093/jjco/hyg093, 14623923.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958, 53:457-481.
12. Davidson NG. Single-agent paclitaxel as first-line treatment of metastatic breast cancer: the British experience. Semin Oncol 1996, 23(5 Suppl 11):6-10.
13. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000, 18(4):724-733.
14. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998, 16(10):3353-3361.
15. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995, 13(5):1152-1159.
16. Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004, 9(6):617-632. 10.1634/theoncologist.9-6-617, 15561806.
17. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30(5 Suppl 16):117-124. 10.1053/j.seminoncol.2003.08.013, 14613032.